Blood pressure normalization in a large population of hypertensive patients treated with perindopril/indapamide combination: results of the OPTIMAX trial.

Détails

Ressource 1Télécharger: 17583188_BIB_8231361779B9.pdf (352.48 [Ko])
Etat: Serval
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_8231361779B9
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Blood pressure normalization in a large population of hypertensive patients treated with perindopril/indapamide combination: results of the OPTIMAX trial.
Périodique
Vascular Health and Risk Management
Auteur(s)
Mourad J.J., Nguyen V., Lopez-Sublet M., Waeber B.
ISSN
1176-6344
Statut éditorial
Publié
Date de publication
2007
Volume
3
Numéro
1
Pages
173-180
Langue
anglais
Résumé
OBJECTIVE: To determine if the fixed-dose perindopril/indapamide combination (Per/Ind) normalizes blood pressure (BP) in the same fraction of hypertensive patients when treated in everyday practice or in controlled trials. METHODS: In this prospective trial, 17 938 hypertensive patients were treated with Per 2 mg/Ind 0.625 mg for 3-6 months. In Group 1 Per/Ind was initiated in newly diagnosed patients (n = 7032); in Group 2 Per/Ind replaced previous therapy in patients already treated but having either their BP still uncontrolled or experiencing side-effects (n = 7423); in Group 3 Per/Ind was added to previous treatment in patients with persistently high BP (n = 3483). BP was considered normalized when < or = 140/90 mm Hg. A multivariate analysis for predictors of BP normalization was performed. RESULTS: Subjects were on average 62 years old and had a baseline BP of 162.3/93.6 mm Hg. After treatment with Per/Ind, BP normalization was reached in 69.6% of patients in the Initiation group, 67.5% in the Replacement Group, and 67.4% in the Add-on Group (where patients were more frequently at risk, diabetic, or with target organ damage). Mean decreases in systolic BP of 22.8 mm Hg and in diastolic BP of 12.4 mm Hg were recorded. CONCLUSIONS: This trial was established to reflect everyday clinical practice, and a treatment strategy based on the Per/Ind combination, administered as initial, replacement, or add-on therapy, led to normalization rates that were superior to those observed in Europe in routine practice. These results support recent hypertension guidelines which encourage the use of combination therapy in the management of arterial hypertension.
Mots-clé
Aged, Aged, 80 and over, Antihypertensive Agents, Blood Pressure, Drug Therapy, Combination, Follow-Up Studies, Humans, Hypertension, Indapamide, Middle Aged, Perindopril, Risk Factors, Treatment Outcome
Pubmed
Création de la notice
06/03/2009 13:00
Dernière modification de la notice
29/05/2019 7:09
Données d'usage